1. Vitamin D Related/Nuclear Receptor Apoptosis
  2. Orphan Nuclear Receptor Ferroptosis
  3. (Z)-GW 441756

(Z)-GW 441756 is a hepatocyte nuclear factor 4α (HNF4α) activator, with an EC50 of 9.2 μM and a Ka of 4.6 μM in human systems. (Z)-GW 441756 directly interacts with the ligand-binding domain of HNF4α via persistent hydrogen bonds and hydrophobic interactions within the binding pocket. (Z)-GW 441756 reduces the accumulation of triglycerides and total cholesterol. (Z)-GW 441756 inhibits ferroptosis through a non-antioxidant mechanism. (Z)-GW 441756 decreases plasma triglyceride and total cholesterol levels in animal models of hyperlipidemia. (Z)-GW 441756 can be used in studies related to hyperlipidemia.

For research use only. We do not sell to patients.

(Z)-GW 441756

(Z)-GW 441756 Chemical Structure

CAS No. : 504433-24-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of (Z)-GW 441756:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

(Z)-GW 441756 is a hepatocyte nuclear factor 4α (HNF4α) activator, with an EC50 of 9.2 μM and a Ka of 4.6 μM in human systems. (Z)-GW 441756 directly interacts with the ligand-binding domain of HNF4α via persistent hydrogen bonds and hydrophobic interactions within the binding pocket. (Z)-GW 441756 reduces the accumulation of triglycerides and total cholesterol. (Z)-GW 441756 inhibits ferroptosis through a non-antioxidant mechanism. (Z)-GW 441756 decreases plasma triglyceride and total cholesterol levels in animal models of hyperlipidemia. (Z)-GW 441756 can be used in studies related to hyperlipidemia[1].

Cellular Effect
Cell Line Type Value Description References
Sf21 IC50
0.003 μM
Compound: GW441756
Inhibition of human N- terminal GST-tagged TrkA cytoplasmic domain (436 to 790 residues) expressed in baculovirus infected sf21 cells using biotinylated peptide substrate incubated for 15 mins followed by addition of ATP measured after 30 mins by TR-FRET
Inhibition of human N- terminal GST-tagged TrkA cytoplasmic domain (436 to 790 residues) expressed in baculovirus infected sf21 cells using biotinylated peptide substrate incubated for 15 mins followed by addition of ATP measured after 30 mins by TR-FRET
[PMID: 27856237]
Sf9 IC50
2 nM
Compound: 2
Inhibition of human TrkA expressed in Sf9 cells by amplified luminescent proximity assay
Inhibition of human TrkA expressed in Sf9 cells by amplified luminescent proximity assay
[PMID: 18646745]
In Vitro

(Z)-GW 441756 ((Z)-19) (0.1-100 μM; 24 h) acts as an HNF4α agonist in HEK293T cells overexpressing HNF4α, with an EC50 of 17 μM for activating the luciferase reporter gene[1].
(Z)-GW 441756 (20-50 μM; 48 h) reduces the accumulation of total cholesterol and triglycerides in OA/PA-induced HepG2 cells, with the 20 μM concentration decreasing TC by 20.34% and TG by 38.23%[1].
(Z)-GW 441756 (10-30 μM; 24 h) protects HepG2 and HT22 cells from RSL3 (HY-100218A)-induced ferroptosis in a concentration-dependent manner via a non-antioxidant mechanism, and treatment with 30 μM significantly increases the cell viability of both cell lines[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HepG2
Concentration: 10, 30 μM+ 0.5 μM RSL3
Incubation Time: 24 h
Result: Significantly increased cell viability in both cell lines at 30 μM.
In Vivo

(Z)-GW 441756 (100 mg/kg; i.p.; two doses with a 24-hour interval) reduces serum triglyceride and total cholesterol levels in an acute dyslipidemia mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (male, 7-8 weeks old)[1]
Dosage: 100 mg/kg
Administration: i.p.; two doses with a 24-hour interval
Result: Produced a larger reduction in serum triglyceride levels than reference compound NCT at 200 mg/kg.
Achieved a comparable reduction in serum total cholesterol levels to reference compound NCT at 200 mg/kg.
Resulted in low serum alanine aminotransferase and aspartate aminotransferase levels.
Molecular Weight

275.30

Formula

C17H13N3O

CAS No.
SMILES

O=C1/C(C2=NC=CC=C2N1)=C\C3=CN(C)C4=C3C=CC=C4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(Z)-GW 441756
Cat. No.:
HY-18314B
Quantity:
MCE Japan Authorized Agent: